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Abstract
Background: Although association of metabolic syndrome (MS) and ischemic heart disease is 
strongly established, it is not known whether presence of MS may differently influence clinical 
responses to cardiac resynchronization therapy (CRT). The aim of this study was to evaluate 
the associations between obesity and metabolic features and the clinical outcome after cardiac 
resynchronization with defibrillator therapy (CRT-D), compared to an implantable cardioverter 
defibrillator (ICD).
Methods: The risk of heart failure (HF) or death and death alone was evaluated in 829 non-
-obese patients, 156 obese patients without MS, and 277 obese patients with MS (all with left 
bundle branch block), who were enrolled in the Multicenter Automatic Defibrillator Implanta-
tion Trial with Cardiac Resynchronization Therapy (MADIT-CRT). 
Results: Obese patients with MS (HR 0.50, 95% CI 0.32–0.77, p = 0.002), obese patients 
without MS (HR 0.57, 95% CI 0.30–1.06, p = 0.077), and non-obese patients (HR 0.48, 95% 
CI 0.37–0.62, p < 0.001) had a similar risk reduction of HF/death in response to CRT-D 
therapy when compared to ICD patients. However, among those with non-ischemic cardiomyo-
pathy, obese patients with MS experienced a 90% reduction for HF/death (HR 0.11, 95% CI 
0.04–0.32, p < 0.001), whereas obese patients without MS had no reduction (HR 0.98, 95% 
CI 0.48–1.98, p = 0.951; interaction p < 0.001). The reverse was observed in ischemic car-
diomyopathy patients: obese patients with MS had no reduction in the risk of HF/death (HR 
0.80, 95% CI 0.48–1.34, p = 0.402), while obese patients without MS showed a significant 
reduction in the risk of events (HR 0.15, 95% CI 0.04–0.65, p = 0.011; interaction p = 0.036). 
Similar trends were observed for the endpoint of death.
Conclusions: Presence of MS differentiates the response to CRT in obese patients with is-
chemic and non-ischemic etiology for HF. (Cardiol J 2016; 23, 3: 344–351)
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Introduction
In the United States (US), two thirds of the 
adult population are overweight or obese [1], and 
the prevalence of obesity is rising worldwide [2]. 
Obesity is a risk factor for heart failure (HF) in the 
general population [3], but the relation of obesity to 
cardiovascular disease outcomes is not very well un-
derstood, and it is known as the “obesity paradox”. 
The presence of obesity in patients with established 
cardiovascular disease is associated with favorable 
clinical prognosis [4]. In our previous analysis, 
weight loss but not presence of obesity increased 
the risk for HF/death after cardiac resynchronization 
therapy with defibrillator (CRT-D) [5].
It has been postulated that metabolic syn-
drome (MS) is a better reflection of complex 
association between metabolic disturbances and 
high cardiovascular risk [6–8]. Indeed, studies 
consistently showed that patients with MS have 
an increased risk for HF and myocardial infarction 
[9–14]. To our knowledge, clinical response to car-
diac resynchronization therapy (CRT) in patients 
with MS has not been evaluated before.
The aim of the current study was to assess 
whether the presence of MS in addition to obe-
sity would affect clinical prognosis after CRT and 
whether ischemic vs. non-ischemic etiology for 
HF in obese patients with and without MS would 
differentiate the response to CRT-D.
Methods
Study population
The results and the protocol of the Multicenter 
Automatic Defibrillator Implantation Trial with 
Cardiac Resynchronization Therapy (MADIT-CRT) 
trial have been previously reported [15]. Patients 
of either sex who were at least 21 years old, with 
ischemic cardiomyopathy (NYHA class I or II) 
or non-ischemic cardiomyopathy (NYHA class II 
only), sinus rhythm, an ejection fraction of 30% 
or less, and prolonged intraventricular conduction 
(QRS duration with ≥ 130 ms) were randomly as-
signed in 3:2 ratio to receive CRT-D or implantable 
cardioverter defibrillator (ICD) only. The MADIT-
-CRT trial was carried out from December 2004 
through September 2010. Post-trial follow-up was 
conducted for all surviving study participants. After 
September 10, 2010, ongoing patient follow-up was 
conducted in 48 US centers that agreed to partici-
pate in the long-term follow-up requested by the 
Food and Drug Administration for patients enrolled 
in the US and in 23 of 24 non-US centers involving 
a total of 854 patients, 407 in the US registry and 
447 in non-US registry. Both phases of the post-
-trial follow-up were approved by the institutional 
review board of each participating center and all the 
patients provided their written informed consent. 
Patients had an ambulatory follow-up 1 month 
after the device implantation, and every 3 months 
thereafter until the termination of the trial, as well 
as every 6 months after the trial. All the patients 
had clinical evaluation at each follow-up appoint-
ment or at any meaningful clinical event.
Definitions of subgroups
In the current analysis, only patients with 
left bundle branch block (LBBB) were evaluated, 
in concordance with previously published clinical 
benefit present exclusively in this group of patients 
[16, 17]. We designed an analysis to compare the 
risk of HF or death, whichever comes first, among 
obese patients with and without MS and non-obese 
patients. Patients with obesity were defined as 
body mass index (BMI) ≥ 30 kg/m2 at baseline 
appointment. Patients with MS were defined based 
on the modified  International Diabetes Federation 
criteria for MS [18]. BMI ≥ 30 kg/m2 at baseline 
was used for definition of obesity and the presence 
of hypertension, or baseline systolic blood pres-
sure ≥ 130 mm Hg, or diastolic blood pressure 
≥ 85 mm Hg was used as a definition for elevated 
blood pressure. The following modification of 
the original definition was applied to account for 
plasma lipids disturbances: fibrates, statins, and 
any other present lipid lowering therapy. Diabetes 
was reported by the enrolling centers at the time 
of device implantation, and in this study, it serves 
as a marker for hyperglycemia. Patients with 
obesity and additionally accompanied by features 
of MS were required to have at least 2 of the 
4 criteria: fibrate, statin or any other lipid lowering 
therapy, diabetes, or hypertension [18]. Patients 
with ischemic heart disease were defined to have 
at least 1 of the following: a documented history of 
myocardial infarction (Q-wave or enzyme-positive), 
a history of a coronary revascularization procedure 
(≥ 1 previous coronary artery bypass graft sur-
geries or percutaneous coronary interventions), 
documented significant coronary artery disease 
at coronary angiography, or aggregate clinical 
findings, for example, history of angina pectoris or 
other coronary-related symptoms or signs.
Endpoints
The primary endpoint was HF or death, which-
ever came first. The secondary endpoint was death. 
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The diagnosis of HF was given by physicians at the 
enrolling centers, when patients presented with 
signs and symptoms consistent with congestive HF 
that prompted intravenous decongestive treatment 
in an outpatient setting or augmented decongestive 
therapy with oral or parenteral drug administra-
tion at the hospital. Adjudication of the endpoints 
of HF or death was carried out by independent 
committees who were blinded to the treatment 
assignment, according to pre-specified criteria.
Statistical analysis
Baseline clinical characteristics were com-
pared using nonparametric Wilcoxon for con-
tinuous variables and the c2 test or Fisher’s test 
for dichotomous variables, as appropriate. We 
performed Kaplan-Meier survival analyses of 
unadjusted cumulative event rates stratified by 
obesity and the presence of MS with the log-rank 
test statistics. We estimated hazard ratios (HR) 
for primary and secondary endpoints using the 
Cox proportional hazards regression method. The 
independent variables were chosen using the best 
subset selection method. We followed this statis-
tical methodology because we wanted to develop 
a parsimonious model which excluded variables that 
were not significantly predictive of the endpoints 
and would have very little impact on the results. In 
this way, we attempted to maximize the statistical 
power, an important consideration in the subgroup 
analysis. Age and sex were forced in the model. 
Possible interactions with clinical covariates were 
systematically tested. Final covariates that were 
used and adjusted for the models are reported in 
specific tables. Analyses were carried out with 
SAS software (version 9.3, SAS institute, Cary, 
North Carolina).
Results
The study population consisted of 1,262 pa-
tients; 277 (22%) obese patients with MS, 156 
(12%) obese patients without MS and 829 (66%) 
non-obese patients in the extended follow-up trial. 
The median follow-up of the enrolled patients was 
5.6 years (interquartile range: 1.8–3.2). Clinical and 
demographic characteristics of the study popula-
tion are presented in Table 1. In summary, obese 
patients with MS were older, more likely male, had 
an ischemic etiology of HF, and lower glomerular 
filtration rate. Usage of angiotensin converting 
enzyme inhibitors, beta-blockers and diuretics was 
similar in both groups.
Obese patients with MS had lower left ven-
tricular (LV) end-diastolic volume and LV end- 
systolic diameter, whereas LV septal and posterior 
wall thicknesses were higher compared to patients 
with obesity only. Patients with MS and obesity had 
higher LV mass compared to non-obese subjects at 
the baseline appointment (Table 1).
The effect of CRT-D vs. ICD therapy on 
mortality and HF/death endpoints
When analyzing all patients combined, CRT-D 
treatment significantly reduced the risk for HF/ 
/death in obese with MS (p < 0.001) and non-obese 
patients (p < 0.001), while reduction in events in 
patients without MS was borderline significant 
(p = 0.088) (Fig. 1A–C). Consistently, multivariate 
Cox model showed that CRT-D treatment in obese 
patients with MS, patients without MS, and non-
obese patients was associated with similar HR of 
0.50, 0.57, and 0.48, respectively (Table 2).
The underlying etiology for HF influenced the 
effect of CRT-D on the risk or HF/death and death 
in obese patients with respect to the presence of 
MS. CRT-D treatment reduced the risk of HF/death 
in obese patients with MS and with non-ischemic 
cardiomyopathy by 90% (p < 0.001). Similarly, for 
death, the same group had 76% reduction in mor-
tality associated with CRT-D vs. ICD treatment.
The opposite was found in patients with is-
chemic cardiomyopathy: obese patients with MS 
did not show benefit from CRT-D, whereas obese 
patients without MS showed substantial 85% re-
duction in HF/death events (p = 0.011) and 81% 
reduction in the risk of death (p = 0.077). The p-
value for interaction was 0.036 when considering 
HF/death events and 0.118 when analyzing death 
(Table 2, Fig. 2).
Non-obese patients showed a similar reduction 
in HF/death and death in the total study population, 
as well as in ischemic and non-ischemic cardiomyo-
pathy subgroups (Table 2, Fig. 3).
Discussion
Our analysis indicates that the presence 
of the MS is associated with different clinical 
responses to CRT-D in patients with ischemic 
and non-ischemic cardiomyopathy. There was no 
evidence of differences in clinical benefit from 
CRT-D between ischemic and non-ischemic in 
non-obese patients. This is an unexpected finding, 
because non-ischemic cardiomyopathy patients 
were reported to present with better clinical re-
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sponse to CRT-D than ischemic cardiomyopathy 
ones [19–21]. Our current data indicate that these 
findings could be associated with the obesity and 
MS status.
Molecular mechanism of CRT is attributed to 
activation of the same pathway as insulin signal-
ing PKB/AKt pathway [22]. It is well known that 
falling heart will switch fuel metabolism from long 
chain fatty acids to glucose, but in people with MS 
also glucose is less available for the heart due to 
the fact that people with MS have profound insulin 
resistance and reduced glucose uptake, especially 
in the presence of ischemia [23]. This may explain 
why the presence of non-ischemic etiology for HF 
is associated with better clinical response after 
CRT-D in general population [19, 24] and in our 
study, in people with MS.
A recent paper by Chokshi et al. [25] suggested 
that implantation of LV assist device reversed 
myocardial lipotoxicity and improved myocardial 
insulin resistance. It is interesting to speculate that 
similarly to LV assist device, the CRT treatment 
also affects cardiac myocardium by direct effect on 
myocardial metabolism [22, 26, 27]. It may affect 
Table 1. Baseline clinical characteristics of MADIT-CRT patients by presence of metabolic syndrome (MS).
Clinical variables Obese patients 
with MS
Obese patients 
without MS
Non-obese  
patients
P: MS vs.  
no MS
P: Overall
Age [years] 63.1 ± 9.4 57.4 ± 11.6 66  ± 10.6 < 0.001 < 0.001
Body mass index [kg/m2] 34.3 ± 4.3 33.6 ± 3.3 25.6 ± 2.9 0.237 < 0.001
Female 71 (26%) 54 (35%) 260 (31%) 0.048 0.087
White 251 (91%) 140 (90%) 758 (92%) 0.832 0.669
CRT-D treatment 156 (56%) 102 (65%) 492 (59%) 0.065 0.182
Ischemic NYHA I and II 156 (56%) 28 (18%) 374 (45%) < 0.001 < 0.001
Non-Ischemic NYHA II 121 (44%) 128 (82%) 455 (55%) < 0.001 < 0.001
Prior MI 111 (41%) 23 (15%) 267 (33%) < 0.001 < 0.001
Prior CABG 80 (29%) 10 (6%) 189 (23%) < 0.001 < 0.001
Prior HF hospitalization 102 (37%) 70 (45%) 310 (38%) 0.101 0.196
Glomerular filtration rate [mL/min] 70 ± 22 74 ± 19 68 ± 20 0.014 0.004
Systolic blood pressure 126 ± 18 119 ± 15 122 ± 17 < 0.001 < 0.001
Diastolic blood pressure 73 ± 11 73 ± 11 71 ± 10 0.791 0.007
Metabolic parameters
Diabetes 169 (61%) 1 (1%) 211 (25%) < 0.001 < 0.001
Hypertension 241 (87%) 60 (38%) 493 (60%) < 0.001 < 0.001
Lipid lowering excluding 61 (22%) 13 (8%) 98 (12%) < 0.001 < 0.001
Statins 234 (84%) 47 (30%) 516 (62%) < 0.001 < 0.001
Baseline drug treatment
ACE-inhibitors 212 (77%) 121 (78%) 634 (76%) 0.807 0.955
Beta-blocker 262 (95%) 148 (95%) 775 (93%) 0.898 0.740
Diuretics 214 (77%) 115 (74%) 530 (64%) 0.408 < 0.001
Baseline echocardiography parameters
LVEF 28.5 ± 3.4 28.5 ± 3.2 28.8 ± 3.5 0.965 0.409
LVEDV indexed by BSA 121 ± 27 126 ± 29 128 ± 31 0.063 0.003
LVESV indexed by BSA 87 ± 22 91 ± 24 92 ± 26 0.089 0.023
LAV indexed by BSA 46 ± 9 46 ± 11 48 ± 10 0.510 0.003
LV mass 229 ± 42 227 ± 47 209 ± 37 0.477 < 0.001
LV septal wall thickness 0.84± 0.07 0.81± 0.07 0.81 ± 0.07 0.001 < 0.001
LV posterior wall thickness 0.83 ± 0.06 0.81 ± 0.07 0.80 ± 0.07 0.004 < 0.001
Values are given as total number of patients and percentage or mean ± standard deviation; ACE — angiotensin converting enzyme;  
BSA — body surface area; CABG — coronary artery bypass graft surgery; HF — heart failure; LV — left ventricle; LVEF — left ventricular  
ejection fraction; LVEDV — left ventricular end-diastolic volume; LVESV — left ventricular end-systolic volume; LAV — left atrial volume; 
NYHA — New York Heart Association class
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heart muscle metabolism towards utilization of long 
chain fatty acids or better utilization of glucose. In 
people with MS and ischemic cardiomyopathy, this 
effect of CRT could be limited and translate into 
higher risk of HF/death.
The molecular mechanism postulated for the 
pathogenesis of cardiac complications in obesity 
includes lipotoxicity [28], inflammation, oxida-
tive stress [29], apoptosis [30] and sympathetic 
overactivation [31]. Obesity leads to the loss of 
cardiomyocytes, cardiac dysfunction and ulti-
mately HF [32]. An unexpected finding of our 
analysis is that patients with obesity without 
metabolic components had better reduction in 
mortality and HF/death when having ischemic 
cardiomyopathy despite similar up front risk. 
This may suggest paradoxical cardioprotection 
of the myocardium from ischemic injury in obese 
patients without disturbances of myocardium 
metabolism/insulin sensitivity reflected as the 
presence of co-morbidities associated with clini-
cal manifestation of MS.
Limitations of the study
Metabolic syndrome diagnosis was a modifica-
tion of original diagnosis based on presence of the 
pharmacological therapy, aiming to treat clinical 
presentation for MS. This was a retrospective, 
nonrandomized post-hoc study, with a relatively 
small number of patients in the subgroup analysis. 
An adjusted multivariate analysis was performed, 
taking into account many confounders associated 
with analyzed endpoints and those that played 
a significant role in the outcome in our population.
Conclusions
Our findings indicate that non-obese ischemic 
and non-ischemic cardiomyopathy patients with 
mild HF derive similar benefit from CRT-D vs. 
ICD. However, the presence of MS differenti-
ates response to CRT stratified by presence of 
ischemic or non-ischemic cardiomyopathy. Obese 
non-ischemic cardiomyopathy patients derive sig-
nificant benefit from CRT-D if they present with 
MS, whereas obese patients without MS show no 
significant reduction in events. On the contrary, 
obese ischemic cardiomyopathy patients with MS 
show no benefit from CRT, while obese ischemic 
patients without MS show significant reduction in 
the risk of events. This study suggests that the risk 
for HF/death and response to CRT in people with 
obesity depends on the presence of MS, especially 
complicated by HF. Although it is only speculative, 
this study also suggests that intrinsic properties of 
myocardium fuel metabolism affected by MS may 
play a role in response to CRT. Future studies are 
needed to investigate the mechanism of CRT in 
Figure 1. Cumulative probability of heart failure (HF)/ 
/death in obese patients with metabolic syndrome (A), 
obese patients without metabolic syndrome (B) and 
non-obese patients (C).
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Figure 2. Cumulative probability of heart failure (HF)/death among patients with ischemic and non-ischemic cardio-
myopathy by obesity status in obese patients with metabolic syndrome (A, B), and obese patients without metabolic 
syndrome (C, D).
Table 2. Risk of heart failure or death with CRT-D vs. ICD by ischemic and non-ischemic etiology and 
by metabolic syndrome (MS).
Patients 
subgroup
 
Obese patients  
with MS
Obese patients  
without MS
Non-obese  
patients
P:  
Metabolic 
obese X 
treatmentPatients; 
events
HR (95% CI)
P
Patients; 
events
HR (95% CI)
P
Patients; 
events
HR (95% CI)
P
Heart failure or death
All patients 270; 84 0.50 (0.32–0.77) 
0.002
154; 40 0.57 (0.30–1.06) 
0.077
816; 246 0.48 (0.37–0.62) 
< 0.001
0.726
Ischemic  
disease
152; 60 0.80 (0.48–1.34) 
0.402
28; 8 0.15 (0.04–0.65) 
0.011
367; 140 0.43 (0.30–0.60) 
< 0.001
0.036
Non-ischemic 
disease
118; 24 0.11 (0.04–0.32) 
< 0.001
126; 32 0.98 (0.48–1.98) 
0.951
449; 106 0.54 (0.37–0.80) 
0.002
< 0.001
Death
All patients 270; 33 0.70 (0.35–1.40) 
0.319
154; 18 0.47 (0.18–1.20) 
0.117
816; 126 0.65 (0.46–0.93) 
0.017
0.506
Ischemic  
disease
152; 25 0.95 (0.43–2.10) 
0.898
28; 5 0.19 (0.03–1.20) 
0.077
367; 84 0.68 (0.44–1.04) 
0.081
0.118
Non-ischemic 
disease
118; 8 0.24 (0.05–1.12) 
0.082
126; 13 0.83 (0.30–2.50) 
0.736
449; 42 0.55 (0.29–1.03) 
0.058
0.214
After adjustment for age, sex, glomerular filtration rate, diabetes, heart rate, ischemic cardiomyopathy, and left atrial volume at baseline in-
dexed by body surface area and interval PR; HR — hazard ratio; CI — confidence interval; CRT-D — cardiac resynchronization with defibrilla-
tor therapy; ICD — implantable cardioverter defibrillator
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Figure 3. Cumulative probability of heart failure (HF)/death 
among non-obese patients with non-ischemic cardiomyo-
pathy (A) and ischemic cardiomyopathy (B).
relation to myocardium fuel metabolism and cel-
lular responses in a falling heart.
Clinical trial registration: NCT00180271, 
NCT01294449, NCT02060110. 
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